# Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications

- Link: https://www.thailand-business-news.com/pr-news/haisco-enters-into-exclusive-license-agreement-with-nuvectis-for-two-drug-candidates-in-oncology-and-complement-indications
- Published: 2026-06-23T20:17:00+07:00
- Author: PR Newswire

BEIJING, June 23, 2026 /PRNewswire/ — On June 23, 2026 (Beijing time), Haisco Pharmaceutical
Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive
licensing agreement with Nuvectis, a U.S. biotechnology company. Under the agreement,
Haisco has granted Nuvectis the exclusive rights to develop, manufacture, and commercialize
its independently developed innovative drug HSK42360 worldwide, excluding Greater
China, as well as its independently developed innovative drug HSK39297 worldwide,
excluding Greater China, India, and certain Southeast Asia territories.

HSK42360 is a best-in-class BRAF paradoxical breaker inhibitor designed to overcome
acquired resistance to current BRAF inhibitors. It demonstrates strong potential
in primary brain tumors and brain metastases and is currently being evaluated in
a Phase I clinical trial in China. HSK39297 is a best-in-class potential once-daily(
QD) CFB inhibitor. Two NDA applications for PNH have been submitted in China, while
several additional indications are advancing through Phase 2 and Phase 3 clinical
development in China.

"This collaboration is highly aligned with our global development strategy and is
expected to generate sustainable value and long-term returns," said Dr. Pangke Yan,
Chief Executive Officer of Haisco. "By partnering with a U.S. biotechnology company
such as Nuvectis, Haisco aims to accelerate the global development of innovative
oncology and complement therapies and bring high-quality treatment options to patients
worldwide."

The collaboration strengthens Haisco’s global presence and enhances the value of
its pipeline by leveraging Nuvectis’ proven research and development capabilities,
extensive industry experience, and established track record in oncology and kidney
diseases.

Under the terms of the agreement, Haisco will receive an upfront and near-term payment
of USD $40 million and is eligible to receive up to USD $1.421 billion in additional
development, regulatory, and commercial milestone payments, as well as tiered royalties
on future net sales. The first four milestones may be payable by Licensee in cash
and/or common stock, provided that the equity consideration shall represent less
than 40% of the total milestone value. If the Licensee sublicenses all or part of
the rights to a third party, or if a Change of Control occurs during the restricted
period, Haisco shall be entitled to share in the corresponding sublicense income
and Change-of-Control payments. In addition, the effectiveness of the agreement 
is subject to certain financing conditions which Nuvectis is required to meet to
ensure sufficient capital for the development of the licensed products.

**About Haisco**

As a benchmark enterprise in China’s innovative pharmaceutical sector, Haisco adheres
to a core strategy of "innovation-driven growth and global expansion." The company
has established a diversified R&D pipeline encompassing small-molecule innovative
drugs, biologics, and high-end generics. Haisco is actively advancing more than 
50 R&D programs across key therapeutic areas including pain management, oncology,
respiratory diseases, autoimmune disorders, metabolic diseases, and central nervous
system disorders; notably, over 10 of these programs have entered pivotal clinical
stages. The company has maintained a strong commitment to R&D, with investment exceeding
15% of revenue in each of the past three years. It has established major R&D centers
in Chengdu, Shanghai, and Silicon Valley, supported by a research team with extensive
global experience, forming an integrated innovation system combining in-house capabilities
and external collaboration.

As early as 2015, Haisco initiated its global strategy and has since actively expanded
into international markets through multiple approaches, including license-out transactions,
co-development partnerships, and overseas mergers and acquisitions.

Looking ahead, Haisco will continue to focus on areas of unmet medical need, strengthen
its capabilities in independent innovation and global collaboration, and strive 
to deliver high-quality, China-originated innovative medicines to patients around
the world.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications ](http://www.prnasia.com/story/archive/4990019_CN90019_0?rand=184833)